BioRestorative Therapies market cap is $10.4 m, and annual revenue was $111 k in FY 2018

BioRestorative Therapies Net income (Q2, 2019)-4.2 M

BioRestorative Therapies EBIT (Q2, 2019)-2.1 M

BioRestorative Therapies Cash, 30-Jun-20191.3 M

USD | FY, 2013 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|

## Revenue | 1.7k | 1.7k | 416.0k | 628.9k | 36.4k | 81.0k | 111.0k |

| 24662% | 51% | (94%) | ||||

## Cost of goods sold | 208.0 | 208.0 | 213.8k | 261.5k | 102.0 | ||

## Gross profit | 1.5k | 1.5k | 202.2k | 367.4k | 36.3k | ||

| 88% | 88% | 49% | 58% | 100% | ||

## Sales and marketing expense | 1.4m | ||||||

## R&D expense | 1.6m | 1.4m | 2.1m | 2.9m | 2.2m | 1.5m | |

## General and administrative expense | 2.3m | 2.3m | 3.9m | 3.3m | 3.9m | 4.0m | |

## Operating expense total | 4.8m | 5.1m | 7.5m | 7.8m | 8.5m | 7.8m | |

## EBIT | (4.8m) | (4.8m) | (4.9m) | (7.2m) | (7.8m) | (8.4m) | (7.6m) |

| (282873%) | (282873%) | (1183%) | (1140%) | (21448%) | (10339%) | (6890%) |

## Interest expense | 371.3k | 371.3k | 285.3k | 263.6k | 221.6k | 468.1k | 932.2k |

## Net Income | (5.8m) | (5.8m) | (5.6m) | (7.9m) | (8.6m) | (9.4m) | (12.5m) |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Cash | 201.1k | 91.8k | 166.6k | 31.8k | 451.7k | 117.5k |

## Accounts Receivable | 93.4k | 6.0k | 38.0k | 29.0k | ||

## Inventories | 18.0k | 1.9k | 29.3k | |||

## Current Assets | 239.8k | 114.3k | 289.3k | 61.7k | 519.7k | 181.0k |

## PP&E | 35.6k | 493.9k | 643.1k | 508.6k | 327.8k | 175.2k |

## Total Assets | 1.4m | 1.7m | 2.0m | 1.6m | 1.8m | 1.2m |

## Accounts Payable | 1.3m | 1.1m | 2.5m | 2.3m | 2.5m | 1.9m |

## Short-term debt | ||||||

## Current Liabilities | 7.5m | 8.5m | 5.6m | 5.8m | 8.4m | 9.3m |

## Long-term debt | ||||||

## Total Debt | ||||||

## Total Liabilities | 8.1m | 5.9m | 6.6m | 8.6m | 9.8m | |

## Additional Paid-in Capital | 13.1m | 18.5m | 29.4m | 37.0m | 44.6m | 55.3m |

## Retained Earnings | (25.4m) | (33.3m) | (42.0m) | (51.4m) | (63.9m) | |

## Total Equity | (6.7m) | (6.9m) | (3.9m) | (5.0m) | (8.6m) | |

## Financial Leverage | -0.2 x | -0.2 x | -0.5 x | -0.3 x | -0.1 x |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|

## Net Income | (5.8m) | (5.6m) | (7.9m) | (8.6m) | (9.4m) | (12.5m) |

## Depreciation and Amortization | 104.8k | 96.7k | 213.8k | 258.4k | 259.3k | 240.4k |

## Accounts Receivable | (93.4k) | 87.4k | (32.0k) | 9.0k | ||

## Inventories | (5.5k) | 613.0 | (6.8k) | |||

## Accounts Payable | 498.5k | (234.6k) | 1.4m | (113.2k) | 186.0k | (516.1k) |

## Cash From Operating Activities | (2.7m) | (3.2m) | (3.1m) | (5.0m) | (3.9m) | (5.1m) |

## Purchases of PP&E | (11.2k) | (168.4k) | (408.1k) | (188.8k) | (3.6k) | (12.9k) |

## Cash From Investing Activities | (11.2k) | (167.4k) | (483.1k) | (188.8k) | (3.6k) | (12.9k) |

## Cash From Financing Activities | 2.9m | 3.3m | 3.7m | 5.1m | 4.3m | 4.8m |

## Interest Paid | 62.3k | 127.1k | 61.5k | 30.4k | 17.5k | 44.8k |

- Source: SEC Filings

- Source: SEC Filings

USD | Y, 2019 |
---|---|

## Financial Leverage | -0.3 x |